

ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

**AUDITED STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED AND THE
YEAR ENDED 31st MARCH, 2018**

(In Lacs)

Particulars	Half Year Ended			For the year ended	Previous Year Ended
	31.03.2018	30.09.2017	31.03.2017	31.03.2018	31.03.2017
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	4684.98	2919.49	3789.22	7604.47	6766.81
II. Other income	62.82	5.90	24.20	68.72	25.02
III. Total Revenue (I + II)	4747.81	2925.39	3813.41	7673.20	6791.82
IV. Expenses:					
(a) Cost of materials consumed	3086.53	2234.60	2505.19	5321.13	4666.02
(b) Changes in Inventories	250.70	-282.44	205.55	-31.74	111.08
(c) Employee benefits expense	290.74	273.71	184.31	564.45	412.40
(d) Finance costs	82.31	75.75	83.50	158.06	152.82
(e) Depreciation and amortization expense	63.74	55.41	64.34	119.15	117.04
(f) Other expenses	611.08	435.76	582.00	1046.84	951.33
Total expenses	4385.09	2792.79	3624.89	7177.88	6410.68
V. Profit before exceptional and extraordinary items and tax (III-IV)	362.71	132.60	188.52	495.31	381.14
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00
VII. Profit before extraordinary items and tax (V - VI)	362.71	132.60	188.52	495.31	381.14
VIII. Extraordinary Items	0.00	0.00	0.00	0.00	0.00
IX. Profit before tax (VII- VIII)	362.71	132.60	188.52	495.31	381.14
X Tax expense:					
(1) Current tax	75.64	27.85	44.92	103.49	87.29
(2) Deferred tax	19.41	0.00	11.50	19.41	11.50
(3) Mat Credit Entitlement	0.00	0.00	0.00	0.00	0.00
XI Profit (Loss) for the period from continuing operations (VII-VIII)	267.66	104.75	132.10	372.41	282.35
XII Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIII Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00



XV	Profit (Loss) for the period (XI + XIV)	267.66	104.75	132.10	372.41	282.35
XVI	Earnings per equity share:					
	(a) Basic & Diluted (Rs.)	5.16	2.25	3.59	7.18	7.67
	(b) Diluted (Rs.)	5.16	2.25	3.59	7.18	7.67

Notes :

- 1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on May 30, 2018.
- 2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 are not applicable.
- 3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.
- 4) The Figures for the half year ended 31st March 2018 and corresponding half year i.e. half year ended 31.03.2017 are the balancing figures between the audited figures in respect of the full financial year.
- 5) As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred in Chapter XB of SEBI (Issue of Capital Disclosure requirements) regulations 2009 are exempted from the compulsory requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not adopted IND -AS for preparation of Financials Results.
- 6) There were no Investors complaints pending as on 31.03.2018.

For ANG Life Sciences India Limited

(Managing Director)
Rajesh Gupta
(DIN : 01423407)



Date : 30.05.2018

Place : Amritsar

ANG Life Sciences India Ltd.
CIN : L24230PB2006PLC030341
Registered Office : 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar
Email ID : cs@anglifesciences.com
Website : www.anglifesciences.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Amount in Lacs)

Sr. No.	Particulars	For the year ended	For the year ended
		31.03.2018	31.03.2017
I.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) <u>Share capital</u>	518.33	368.25
	(b) <u>Reserves and surplus</u>	1798.50	380.66
	Sub-total-Shareholders' Fund	2316.83	748.91
2	Non-current liabilities		
	(a) <u>Long-term borrowings</u>	768.33	496.30
	(b) <u>Other Long-term liabilities</u>	149.82	0.00
	(b) <u>Deferred Tax Liabilities (Net)</u>	36.95	17.54
	Sub-total-non Current Liabilities	955.10	513.84
3	Current liabilities		
	(a) <u>Short Term Borrowings</u>	639.89	661.35
	(b) <u>Trade Payables</u>	2231.52	2139.18
	(c) <u>Other current liabilities</u>	568.86	529.24
	(d) <u>Short-term provisions</u>	104.31	91.29
	Sub-total-Current Liabilities	3544.60	3421.07
	TOTAL EQUITY AND LIABILITIES	6816.53	4683.82
II.	ASSETS		
	Non-current assets		
1	(a) <u>Fixed assets</u>		
	(i) <u>Tangible assets</u>	2104.13	897.30
	(b) <u>Deferred Tax Assets (Net)</u>	0.00	0.00
	(c) <u>Other non-current assets</u>	22.93	8.79
	(d) <u>Other non-current Investments</u>	2.00	2.00
	Sub-total-non Current Assets	2129.06	908.10
2	Current assets		
	(a) <u>Inventories</u>	774.29	584.08
	(b) <u>Trade receivables</u>	3215.02	2555.61
	(c) <u>Cash and cash equivalents</u>	147.94	90.97
	(d) <u>Short-term loans and advances</u>	550.21	545.06
	Sub-total-Current Assets	4687.46	3775.72
	TOTAL ASSETS	6816.53	4683.82
	See accompanying notes forming part of the financial statements.		

For ANG Life Sciences India Limited

(Managing Director)
Rajesh Gupta
(DIN : 01423407)



Date : 30.05.2018
Place : Amritsar

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/2018-19/BSE-34
To

Date 30/05/2018

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

In accordance with Reg. 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligation and Disclosure Requirements), Regulations 2016, it is hereby declared that M/s Ajay K. Khanna & Co., Chartered Accountants, Statutory Auditors of the Company have issued an Auditor's Report with unmodified opinion on the standalone Audited Financial Results of the Company for the half year and financial year ended March 31, 2018 as approved at the Board Meeting held on 30th May, 2018.

Kindly take the same on your record and acknowledge the receipt.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**


Rajesh Gupta
(DIN: 01423407)
Managing Director



Factory:
Village: Kishanpura,
Nalagarh Road,
Tehsil: Baddi,
Distt.: Solan,
HP-174101

Regd. Office : SCO-113,
DARBARA COMPLEX,
First Floor, B-BLOCK,
Ranjit Avenue, Amritsar.
Ph. 0183-5133455, 5133458
E mail :- operations@anglifesciences.com
website : www.anglifesciences.com



Auditor's Report on Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors of
ANG Lifesciences India Limited


We have audited the yearly standalone financial results of ANG Lifesciences India Limited for the year ended 31st march, 2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

These financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25/Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the year ended 31st March 2018.

Date:- 30.05.2018
Place:- Amritsar

For Ajay K Khanna & Co.
Chartered Accountants

(Bhupinder Singh)
Partner
M. No. 513899
F.R.No.012303N